Cancer

$11.5 million supports innovation in leukemia research

Extending its standing as one of the top leukemia programs in the United States, Washington University School of Medicine in St. Louis has been awarded an $11.5 million grant to further high-level investigations into leukemia and related blood cancers. The grant, from the National Institutes of Health (NIH), funds a prestigious Specialized Program in Research

SLU Scientist Tackles Debilitating Side Effects of Cancer and Pain Medications

With a pair of RO1 grants from the National Institutes of Health, pain researcher Daniela Salvemini, Ph.D., will embark on two new research projects, studying chemotherapy-induced cognitive impairment, or “chemo brain,” symptoms and unwanted side effects of opioids.  Salvemini, who is professor of pharmacology and physiology at Saint Louis University, has spent her career attempting

Siteman Cancer Center to offer newest form of proton therapy

Cancer patients in Missouri, Southern Illinois and beyond will have access to a new generation of proton therapy in early 2020. Known as pencil-beam scanning, the technology delivers extremely precise treatments of proton therapy, a type of radiation therapy used to treat cancers of the head, chest, spine and other particularly sensitive areas, as well

October 23rd, 2018|Categories: Around The State, Cancer, Disease Specific|Tags: , |

Surgery Remains Best Option for Rare Bladder Cancer

In a recent paper published in the World Journal of Urology, Saint Louis University researchers reviewed data for patients with a rare type of bladder cancer, examining the treatments they received and the subsequent five-year-survival rates. Zachary Hamilton, M.D., assistant professor of urologic surgery at SLU and a SLUCare urologic oncologist, reports that surgery for

September 28th, 2018|Categories: Around The State, Cancer, Disease Specific|Tags: , |

New clues found to understanding relapse in breast cancer

A large genomic analysis has linked certain DNA mutations to a high risk of relapse in estrogen receptor positive breast cancer, while other mutations were associated with better outcomes, according to researchers from Washington University School of Medicine in St. Louis, the Baylor College of Medicine and the University of British Columbia. The knowledge could

September 20th, 2018|Categories: Around The State, Cancer|Tags: , |